Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 20Active not recruiting 14Completed 5Not yet recruiting 3Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Myelodysplastic Syndromes 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Acute 1Leukemia, Biphenotypic, Acute 1Blastic Plasmacytoid Dendritic Cell Neoplasm 1

Interventions

pembrolizumab 28Carboplatin 18Cisplatin 15Nivolumab 13Pemetrexed 12Paclitaxel 11Specimen Handling 10Ipilimumab 10Gemcitabine 10venetoclax 8durvalumab 8atezolizumab 8Radiotherapy 8Radiosurgery 8Magnetic Resonance Spectroscopy 8Docetaxel 7Cyclophosphamide 7Biopsy 7fludarabine 6enzalutamide 6Bevacizumab 6tislelizumab 5tazemetostat 5X-Rays 5Trastuzumab 5Surveys and Questionnaires 5Practice Guidelines as Topic 5Interviews as Topic 5Injections 5Dexamethasone 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Decitabine × 90 days × Clear all
NCT03404193 2026-03-10

Venetoclax and Decitabine in Treating Participants With Relapsed/Refractory Acute Myeloid Leukemia or Relapsed High-Risk Myelodysplastic Syndrome

M.D. Anderson Cancer Center

Phase 2 Terminated
235 enrolled
MyeloidOther hematologic neoplasm

Blastic Plasmacytoid Dendritic Cell Neoplasm, Myelodysplastic Syndromes, Leukemia, Biphenotypic, Acute, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡